Neurosterix

Based in Geneva, Switzerland, and founded in 204, Neurosterix, a spinoff of Addex operates as a pharmaceutical research company dedicated to advancing the treatment of neurological disorders. In April 2024, the firm raised USD 63 million in series A funding led by investor Perceptive Xontogeny Venture Fund, with participation from other investors Perceptive Advisors and Acorn Bioventures. The company by leveraging its drug discovery and development techniques, engages in the creation of allosteric modulators, which offer promising avenues for enhancing the efficacy and safety of neurological medications. Neurosterix's core focus lies in the identification and development of allosteric modulators, which exert their effects by binding to regulatory sites on target receptors.

By modulating neurotransmission outside of traditional binding sites, these molecules offer potential advantages in terms of efficacy, safety, and tolerability. As of April 2024, the firm’s lead program is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator (M4 PAM) for the treatment of schizophrenia. The company plans to utilize the April 2024 funding to develop new medicines, overcome the burdens of traditional drugs, and provide patients with the potential to improve their lives dramatically.